Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.
Nacuity Pharmaceuticals has raised $16.5M in total funding. The most recent round was Series B. The last funding was announced in June 2022.
Nacuity Pharmaceuticals's investors include Foundation Fighting Blindness, Maxim Group, Retinal Degeneration Fund, Hugo Peris.
Nacuity Pharmaceuticals is headquartered in Fort Worth, United States.
Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.
Nacuity Pharmaceuticals is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nacuity Pharmaceuticals — Funding & Investors." VCBacked, June 15, 2022, https://www.vcbacked.co/company/nacuity-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2022). Nacuity Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/nacuity-pharmaceuticals
{{cite web |title=Nacuity Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/nacuity-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated